Energy News / Shareholders Foundation, Inc.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Former Employee Alert: Investigation over Potential Wrongdoing

Via: ReleaseWire

Updated 8:00 AM CDT, Tue, April 14,2015

An investigation on behalf of former employees of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) concerning potential breaches of fiduciary duties was announced and employees of AcelRx Pharmaceuticals stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (ReleaseWire) -- 04/14/2015 -- An investigation on behalf of former employees of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) concerning potential Breaches of Fiduciary Duty was announced.

Former employees of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the investigation by a law firm employees of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) may be eligible to file a complaint for putting stock options at risk if they can prove their employer violated its fiduciary duty to them.

On July 25, 2014, AcelRx Pharmaceuticals Inc announced that the FDA has issued a Complete Response Letter for the Company's new drug application ("NDA") for Zalviso™ (sufentanil sublingual tablet system). The Company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with theFDA. AcelRx Pharmaceuticals said that the Complete Response Letter contains requests for additional information on the Zalviso System to ensure proper use of the device. AcelRx Pharmaceuticals said that additional bench testing will be required and human factors testing may be required to address certain items in the Complete Response Letter.

Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) dropped from as high as $11.38 per share during July 25, 2014, to $6.14 per share on July 28, 2014,

On September 26, 2014, AcelRx Pharmaceuticals Inc provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso™ (sufentanil sublingual tablet system). Among other things, AcelRx Pharmaceuticals Inc said that the timing of the filing of the NDA could be later than the first quarter of 2015 and that theFDA communicated that the planned resubmission will qualify as a Class 2 resubmission with a review period of six months.

On October 1, 2014, a lawsuit was filed against AcelRx Pharmaceuticals Inc over alleged Securities Laws Violations. The plaintiff claims that defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose between December 2, 2013 and September 25, 2014 that the Instructions for Use (IFU) for Zalviso were not designed to adequately address the risk of the inadvertent misplacement of tablets, that AcelRx Pharmaceuticals Inc had not submitted to the U.S. Food and Drug Administration ("FDA") sufficient data to support the shelf life of the product, and that, as a result of the foregoing, Defendants' statements about Zalviso, including the drug's regulatory approval and financial prospects, were materially false and misleading at all relevant times and/or lacked a reasonable basis.

On March 9, 2015, AcelRx Pharmaceuticals Inc provided an update on the timing and potential content of the resubmission of the New Drug Application ("NDA") for Zalviso. AcelRx Pharmaceuticals Inc said that late last week it received correspondence from the Food and Drug Administration ("FDA") stating that in addition to the bench testing and two Human Factors studies it has performed, an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) declined to as low as $3.95 per share on March 12, 2015.

Those who are former employees of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.releasewire.com/press-releases/acelrx-pharmaceuticals-inc-nasdaqacrx-former-employee-alert-investigation-over-potential-wrongdoing-591835.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com